- Home
- BBT vs RARE Comparison
BBT vs RARE Comparison
Compare BBT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBT
- RARE
- Stock Information
- Founded
- BBT 1846
- RARE 2010
- Country
- BBT United States
- RARE United States
- Employees
- BBT N/A
- RARE N/A
- Industry
- BBT Banks
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- BBT Finance
- RARE Health Care
- Exchange
- BBT Nasdaq
- RARE Nasdaq
- Market Cap
- BBT 2.2B
- RARE 2.6B
- IPO Year
- BBT N/A
- RARE 2014
- Fundamental
- Price
- BBT N/A
- RARE $29.00
- Analyst Decision
- BBT Hold
- RARE Strong Buy
- Analyst Count
- BBT 1
- RARE 14
- Target Price
- BBT $33.00
- RARE $86.64
- AVG Volume (30 Days)
- BBT 537.9K
- RARE 1.4M
- Earning Date
- BBT 11-08-2025
- RARE 11-04-2025
- Dividend Yield
- BBT 5.04%
- RARE N/A
- EPS Growth
- BBT 2.47
- RARE N/A
- EPS
- BBT 2.10
- RARE N/A
- Revenue
- BBT $345,393,000.00
- RARE $610,159,000.00
- Revenue This Year
- BBT $47.36
- RARE $19.72
- Revenue Next Year
- BBT $79.15
- RARE $23.29
- P/E Ratio
- BBT $12.18
- RARE N/A
- Revenue Growth
- BBT 2.90
- RARE 26.77
- 52 Week Low
- BBT $22.27
- RARE $25.81
- 52 Week High
- BBT $32.36
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- BBT N/A
- RARE 40.55
- Support Level
- BBT N/A
- RARE $31.22
- Resistance Level
- BBT N/A
- RARE $31.80
- Average True Range (ATR)
- BBT 0.00
- RARE 0.97
- MACD
- BBT 0.00
- RARE -0.09
- Stochastic Oscillator
- BBT 0.00
- RARE 1.10
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.